n.hartmann

TL2 · Palermo

Contributes reviews on supplier material. Based in Palermo.

Joined 17 November 2024 · last posted 1d

96Posts here

2Topics

1Solutions

112Likes received

118Likes given

20Badges

92Days visited

1kPosts read

Recent activity

Full stream

Packaging that arrived damaged: documenting it properly Replied, post #50 · Sourcing › Logistics · 27 Jul 2026 · 31 likes Sensible. I would want the same detail before I acted on it either.
The five documentation pages worth reading before you post anything — a second dataset Replied, post #3 · marked as the solution · Start Here › Welcome · 27 Jul 2026 · 26 likes The compound and evidence pages are updated regularly and they are worth reading when you are new. They answer the meta questions like "do we have data on this" and…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #66 · Compounds › Repair & healing peptides · 25 Jul 2026 · 2 likes Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by…
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #31 · Lounge › Off topic · 22 Jul 2026 · 1 like A digression that keeps occurring to me: the most-linked documents here are the dullest ones. Nothing gets cited like the unit-arithmetic page. That holds for the case…
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #38 · Compounds › Retatrutide · 18 Jul 2026 · 1 like What I can speak to on glucagon receptor agonist is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #110 · Evidence › Journal club · 16 Jul 2026 · 0 likes Coming back to post #107, because the follow-up matters more than the original answer. On SURMOUNT-OSA: the maintained page in the documentation commons covers the…
How shortages have affected compounding permissions Replied, post #38 · Access › Shortages · 14 Jul 2026 · 4 likes Where an alternative within the class is available, the comparison is a clinical one and the doses are not equivalent. I have left out the parts I could not verify.
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #51 · Clinical › Comorbidities · 13 Jul 2026 · 9 likes Nothing here is medical advice and clinicians posting in this subcategory say so on their own account rather than because a rule requires it. I would not lead a…
Follow-up: Reading an interaction checker output critically Replied, post #43 · Practice › Interactions · 12 Jul 2026 · 0 likes Oral medications with a narrow therapeutic index are the ones where that matters most. The interaction is about rate and timing rather than about the total absorbed, in…
Follow-up: Comparing two chromatograms from different laboratories, properly Replied, post #57 · Analytics › HPLC & UHPLC · 9 Jul 2026 · 1 like Post #55 answers the question as asked. The question underneath it is different. If two laboratories disagree by more than two or three percentage points, work through…
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #29 · Compounds › Secretagogues & GH axis · 8 Jul 2026 · 0 likes I read post #28 twice before replying, because I had assumed the opposite. CJC-1295 with and without DAC: the version with a drug affinity complex binds albumin…
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #60 · Access › International · 6 Jul 2026 · 4 likes No disagreement from me. Posting only so the question does not look ignored.